Thulium Fiber Laser (TFL) vs Holmium MOSES for Treatment of Benign Prostatic Hyperplasia (BPH) (NCT05240001)
Thulium Fiber Laser (TFL) Versus Holmium MOSES Laser Enucleation of the Prostate for Treatment of Benign Prostatic Hyperplasia (BPH): A Randomized Prospective Clinical Study
๐ฉบ Plain-English Summary (8th-Grade Level)
Benign prostatic hyperplasia (BPH), the non-cancerous enlargement of the prostate, places pressure on the urethra and causes urination and bladder problems. Transurethral Resection of the Prostate (TURP) remains the gold standard treatment in most centres for BPH. However, morbidity after TURP is high, especially bleeding requiring blood transfusion and late postoperative bleeding. Holmium laser enucleation of the prostate (HoLEP) is a safe and effective procedure which has demonstrated comparable results to TURP. HOLEP also offers patients the alternative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay. The main reason HoLEP has yet to become the new standard for treatment of symptomatic BPH is due the complexity of this procedure as compared to TURP. Furthermore, the HoLEP can be used with the MOSESTM system, a system that allows for more efficiency and ease of use of the HoLEP. Thulium fiber laser (TFL) enucleation of the prostate is an emerging technology for endoscopic prostate enucleation that is notable for its high wavelength and pulsed mode of action. Recent studies have shown TFL enucleation of the prostate to be a safe and highly efficacious treatment modality for the management of large volume (\> 80 cm3) glands in BPH. Due to its novelty, further studies are needed to broaden the investigators' understanding of the TFL and comprehend the full implications and benefits of this new technology, as well its limitations. The aim of this study is to whether Thulium Fiber laser enucleation of the prostate (ThuFLEP) and Holmium laser enucleation using MOSESโข (M-HoLEP) have comparable length of hospital stay, as well as intraoperative and postoperative outcomes.
Who can join: Review the eligibility criteria below.
Location: Thunder Bay Regional Health Sciences Centre โ Thunder Bay, Ontario
Age range: 50 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- Thunder Bay Regional Health Sciences Centre โ Thunder Bay, Ontario
๐ Contact the Study Coordinator
Phone: (807) 684-6608
Email: siddiqur@tbh.net
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Benign Prostatic Hyperplasia
- PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs โ La Mesa, California
- Comparing UroLift Experience Against Rezลซm โ Los Angeles, California
- Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocrossยฎ Expander System & Retrieval Sheath โ Maywood, Illinois
- Optilumeโข BPH Catheter System in Men With Symptomatic BPH โ Little Rock, Arkansas
- Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of Prostate โ Miami, Florida
- Laser Prostatectomy Database and Registry โ Indianapolis, Indiana
Explore by condition: All Benign Prostatic Hyperplasia clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.